Journalists have learned from Hybio Pharmaceutical (300199) that on December 25, a signing ceremony was held in Beijing between Hybio Pharmaceutical and the world-renowned pharmaceutical company Dr. Reddy’s Laboratories. The two parties formally signed a non-binding term sheet for strategic cooperation in the field of peptide Active Pharmaceutical Ingredients (APIs) and related formulations, marking a successful start to their strategic partnership.
It is reported that this cooperation resulted from in-depth prior consultations and strategic alignment. In September 2025, the global CEO of Dr. Reddy’s led a team to visit Hybio’s headquarters and production bases. The two sides held deep discussions on key issues such as peptide drug R&D innovation, global commercialization strategies, and potential strategic directions, followed by multiple rounds of face-to-face exchanges during international conferences such as CPHI.
According to the cooperation framework, the two parties have reached a preliminary consensus on the scope of cooperation and overall strategy for multiple peptide API varieties. Hybio Pharmaceutical will serve as the preferred API development and supply partner for Dr. Reddy’s peptide formulation business. For certain products, the two parties will adopt preferred or semi-exclusive cooperation arrangements and promote long-term stable global cooperation under the premise of meeting minimum purchase commitments. Furthermore, both parties will engage in exploratory discussions regarding generic drugs, oligonucleotides, and other areas to layout a broader range of therapeutic fields.
Dr. Reddy’s possesses a mature regulatory registration, formulation development, and commercialization network across more than 80 markets worldwide, viewing the peptide business as a strategic growth direction. Hybio Pharmaceutical, on the other hand, boasts an advanced R&D platform, large-scale manufacturing capabilities, and a continuously expanding product pipeline in the peptide API field. By complementing each other's strengths and synergizing early-stage R&D, the two companies are expected to improve development efficiency and bring high-quality peptide products to the global market more rapidly.
Zeng Shaogui, Chairman and President of Hybio Pharmaceutical, stated that this strategic cooperation with Dr. Reddy’s is a significant milestone in the company’s peptide internationalization strategy. In the future, both parties will use peptide API cooperation as a starting point to deepen exploration in peptide formulation development and oligonucleotides, leveraging their respective advantages in technology, production capacity, and market reach to drive innovative development in the peptide drug sector.
Erez Israeli, CEO of Dr. Reddy’s, expressed that Hybio Pharmaceutical’s deep technical expertise and mature industrialization capabilities in the peptide API field are highly complementary to Dr. Reddy’s strengths in global formulation R&D, regulatory filing, and market networks. He firmly believes that this deep cooperation will not only achieve win-win commercial value but is also expected to create a globally exemplary model for peptide industry cooperation, contributing to the high-quality development of the global peptide industry.

https://finance.eastmoney.com/a/202512263603185371.html